News|Videos|November 13, 2023
MARIPOSA-2: Amivantamab + Lazertinib + Chemotherapy in EGFR-Mutated Advanced NSCLC
Shared insight from key opinion leaders on results from MARIPOSA-2 and the role of amivantamab plus lazertinib and chemotherapy in patients with advanced NSCLC following progression on osimertinib.
Advertisement
Episodes in this series
Advertisement
Related to this article
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.
Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.
Firmonertinib did not improve PFS in the phase 3 FURVENT trial in patients with EGFR exon 20 insertion–mutant NSCLC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
2
Durability of PFS and OS Benefit vs. Historical Control
3
How Disease Burden Shapes First-Line RCC Treatment Selection
4
Rivoceranib Plus Camrelizumab Resubmitted to FDA in Frontline HCC
5